Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 12
Submit an article Journal homepage
231
Views
24
CrossRef citations to date
0
Altmetric
Review

The parkin protein as a therapeutic target in Parkinson's disease

Konstanze F Winklhofer Ludwig-Maximilians-University, Adolf-Butenandt-Institute, Department of Biochemistry, Neurobiochemistry, Schillerstrasse 44, 80336 Munich, Germany +49 89 2180 75 483; +49 89 2180 75 415; [email protected]
, MD PhD
Pages 1543-1552 | Published online: 18 Nov 2007

Bibliography

  • SPILLANTINI MG, SCHMIDT ML, LEE VM et al.: α-synuclein in Lewy bodies. Nature (1997) 388(6645):839-840.
  • BRAAK H, GHEBREMEDHIN E, RUB U, BRATZKE H, DEL TREDICI K: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. (2004) 318(1):121-134.
  • BOVE J, PROU D, PERIER C, PRZEDBORSKI S: Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2(3):484-494.
  • FLEMING SM, FERNAGUT PO, CHESSELET MF: Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx (2005) 2(3):495-503.
  • MELROSE HL, LINCOLN SJ, TYNDALL GM, FARRER MJ: Parkinson's disease: a rethink of rodent models. Exp. Brain Res. Experimentelle Hirnforschung (2006) 173(2):196-204.
  • MANNING-BOG AB, LANGSTON JW: Model fusion, the next Phase in developing animal models for Parkinson's disease. Neurotox. Res. (2007) 11(3-4):219-240.
  • KLEIN C, SCHLOSSMACHER MG: Parkinson disease, 10 years after its genetic revolution. Multiple clues to a complex disorder. Neurology (2007).
  • THOMAS B, BEAL MF: Parkinson's disease. Hum. Mol. Genet. (2007) 16(Spec No 2):R183-R194.
  • KITADA T, ASAKAWA S, HATTORI N et al.: Mutations in the parkin gene cause autosomal parkinsonism. Nature (1998) 392(6676):605-608.
  • MATA IF, LOCKHART PJ, FARRER MJ: Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet. (2004) 13(Spec No 1):R127-R133.
  • WEST AB, MAIDMENT NT: Genetics of parkin-linked disease. Hum. Genet. (2004) 114(4):327-336.
  • LOHMANN E, PERIQUET M, BONIFATI V et al.: How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. (2003) 54(2):176-185.
  • SCHLOSSMACHER MG, FROSCH MP, GAI WP et al.: Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. (2002) 160(5):1655-1667.
  • FARRER M, CHAN P, CHEN R et al.: Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. (2001) 50(3):293-300.
  • SASAKI S, SHIRATA A, YAMANE K, IWATA M: Parkin-positive autosomal recessive juvenile parkinsonism with α-synuclein-positive inclusions. Neurology (2004) 63(4):678-682.
  • PRAMSTALLER PP, SCHLOSSMACHER MG, JACQUES TS et al.: Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol. (2005) 58(3):411-422.
  • VAN DE WARRENBURG BP, LAMMENS M, LUCKING CB et al.: Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology (2001) 56(4):555-557.
  • GAIG C, MARTI MJ, EZQUERRA M et al.: G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J. Neurol. Neurosurg. Psychiatry (2007) 78(6):626-628.
  • GIASSON BI, COVY JP, BONINI NM et al.: Biochemical and pathological characterization of Lrrk2. Ann. Neurol. (2006) 59(2):315-322.
  • ZIMPRICH A, BISKUP S, LEITNER P et al.: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 44(4):601-607.
  • PALACINO JJ, SAGI D, GOLDBERG MS et al.: Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. (2004) 279(18):18614-18622.
  • WHITWORTH AJ, WES PD, PALLANCK LJ: Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov. Today (2006) 11(3-4):119-126.
  • CLARK IE, DODSON MW, JIANG C et al.: Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature (2006) 441(7097):1162-1166.
  • PARK J, LEE SB, LEE S et al.: Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature (2006) 441(7097):1157-1161.
  • YANG Y, GEHRKE S, IMAI Y et al.: Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA (2006) 103(28):10793-10798.
  • EXNER N, TRESKE B, PAQUET D et al.: Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. (2007) 27(45):12413-12418.
  • PICKART CM, FUSHMAN D: Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. (2004) 8(6):610-616.
  • KERSCHER O, FELBERBAUM R, HOCHSTRASSER M: Modification of proteins by ubiquitin and ubiquitin-like proteins. Ann. Rev. Cell Dev. Biol. (2006) 22:159-180.
  • MOORE DJ: Parkin: a multifaceted ubiquitin ligase. Biochem. Soc. Transactions (2006) 34(Part 5):749-753.
  • KO HS, KIM SW, SRIRAM SR, DAWSON VL, DAWSON TM: Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J. Biol. Chem. (2006) 281(24):16193-16196.
  • KO HS, VON COELLN R, SRIRAM SR et al.: Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. (2005) 25(35):7968-7978.
  • HENN IH, BOUMAN L, SCHLEHE JS et al.: Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. (2007) 27(8):1868-1878.
  • TAN EK, PUONG KY, CHAN DK et al.: Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association. Hum. Genet. (2005) 118(3-4):484-488.
  • LESNE S, KOH MT, KOTILINEK L et al.: A specific amyloid-β protein assembly in the brain impairs memory. Nature (2006) 440(7082):352-357.
  • CHEN ZJ: Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. (2005) 7(8):758-765.
  • HAGLUND K, DIKIC I: Ubiquitylation and cell signaling. EMBO J. (2005) 24(19):3353-3359.
  • KRAPPMANN D, SCHEIDEREIT C: A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep. (2005) 6(4):321-326.
  • FALLON L, BELANGER CM, CORERA AT et al.: A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. (2006) 8(8):834-842.
  • MOCHIZUKI H: Gene therapy for Parkinson's disease. Expert Rev. Neurother. (2007) 7(8):957-960.
  • MANFREDSSON FP, BURGER C, SULLIVAN LF et al.: rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp. Neurol. (2007) 207(2):289-301.
  • PATERNA JC, LENG A, WEBER E, FELDON J, BUELER H: DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol. Ther. (2007) 15(4):698-704.
  • VERCAMMEN L, VAN DER PERREN A, VAUDANO E et al.: Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol. Ther. (2006) 14(5):716-723.
  • YAMADA M, MIZUNO Y, MOCHIZUKI H: Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. (2005) 16(2):262-270.
  • YASUDA T, MIYACHI S, KITAGAWA R et al.: Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience (2007) 144(2):743-753.
  • LO BIANCO C, SCHNEIDER BL, BAUER M et al.: Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (2004) 101(50):17510-17515. [Epub 12004 Dec 17502].
  • KLEIN RL, DAYTON RD, HENDERSON KM, PETRUCELLI L: Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci. Lett. (2006) 401(1-2):130-135.
  • HENN IH, GOSTNER JM, TATZELT J, WINKLHOFER KF: Pathogenic mutations inactivate parkin by distinct mechanisms. J. Neurochem. (2005) 92:114-122.
  • WINKLHOFER KF, HENN IH, KAY-JACKSON P, HELLER U, TATZELT J: Inactivation of parkin by oxidative stress and C-terminal truncations; a protective role of molecular chaperones. J. Biol. Chem. (2003) 278:47199-47208.
  • LAVOIE MJ, OSTASZEWSKI BL, WEIHOFEN A, SCHLOSSMACHER MG, SELKOE DJ: Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. (2005) 11(11):1214-1221.
  • CHUNG KK, THOMAS B, LI X et al.: S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 304(5675):1328-1331.
  • YAO D, GU Z, NAKAMURA T et al.: Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA (2004) 101(29):10810-10814.
  • GU WJ, CORTI O, ARAUJO F et al.: The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis. (2003) 14(3):357-364.
  • COOKSON MR, LOCKHART PJ, MCLENDON C et al.: RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. (2003) 12(22):2957-2965.
  • SRIRAM SR, LI X, KO HS et al.: Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. (2005) 14(17):2571-2586.
  • WANG C, TAN JM, HO MW et al.: Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem. (2005) 93(2):422-431.
  • WANG C, KO HS, THOMAS B et al.: Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. (2005) 14(24):3885-3897.
  • HAMPE C, ARDILA-OSORIO H, FOURNIER M, BRICE A, CORTI O: Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. (2006) 15(13):2059-2075.
  • WONG ES, TAN JM, WANG C et al.: Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem. (2007) 282(16):12310-12318.
  • KYRATZI E, PAVLAKI M, KONTOSTAVLAKI D, RIDEOUT HJ, STEFANIS L: Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells. J. Neurochem. (2007) 102(4):1292-1303.
  • KIERAN D, KALMAR B, DICK JR et al.: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. (2004) 10(4):402-405.
  • BEHL C: Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-β estradiol and induces the activity of the transcription factor NF-κB. J. Neural. Transm. (2000) 107(4):393-407.
  • GAL S, ZHENG H, FRIDKIN M, YOUDIM MB: Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. (2005) 95(1):79-88.
  • ROGHANI M, BEHZADI G: Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. (2001) 892(1):211-217.
  • ZHENG H, GAL S, WEINER LM et al.: Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. (2005) 95(1):68-78.
  • SHOULSON I: DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neurol. (1998) 44(3 Suppl. 1):S160-S166.
  • ETMINAN M, GILL SS, SAMII A: Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. (2005) 4(6):362-365.
  • BJELAKOVIC G, NIKOLOVA D, GLUUD LL, SIMONETTI RG, GLUUD C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 297(8):842-857.
  • MILLER ER III, PASTOR-BARRIUSO R, DALAL D et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Internal Med. (2005) 142(1):37-46.
  • PAHL HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene (1999) 18(49):6853-6866.
  • HAYDEN MS, GHOSH S: Signaling to NF-kappaB. Genes Dev. (2004) 18(18):2195-2224.
  • HUNOT S, BRUGG B, RICARD D et al.: Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. USA (1997) 94(14):7531-7536.
  • MORAN LB, CROISIER E, DUKE DC et al.: Analysis of α-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol. (Berl) (2007) 113(3):253-263.
  • CAMANDOLA S, MATTSON MP: NF-κB as a therapeutic target in neurodegenerative diseases. Expert Opin. Ther. Targets (2007) 11(2):123-132.
  • MEFFERT MK, BALTIMORE D: Physiological functions for brain NF-kappaB. Trends Neurosci. (2005) 28(1):37-43.
  • YAMAMOTO A, FRIEDLEIN A, IMAI Y et al.: Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J. Biol. Chem. (2005) 280(5):3390-3399.
  • AVRAHAM E, ROTT R, LIANI E, SZARGEL R, ENGELENDER S: Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J. Biol. Chem. (2007) 282(17):12842-12850.
  • PAPA S, ZAZZERONI F, PHAM CG, BUBICI C, FRANZOSO G: Linking JNK signaling to NF-kappaB: a key to survival. J. Cell Sci. (2004) 117(Part 22):5197-5208.
  • DAVIS RJ: Signal transduction by the JNK group of MAP kinases. Cell (2000) 103(2):239-252.
  • PENG J, ANDERSEN JK: The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease. IUBMB Life (2003) 55(4-5):267-271.
  • WAETZIG V, HERDEGEN T: Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci. Lett. (2004) 361(1-3):64-67.
  • CHA GH, KIM S, PARK J et al.: Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. USA (2005) 102(29):10345-10350.
  • MATHIASEN JR, MCKENNA BA, SAPORITO MS et al.: Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells. Brain Res. (2004) 1003(1-2):86-97.
  • SAPORITO MS, BROWN EM, MILLER MS, CARSWELL S: CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. (1999) 288(2):421-427.
  • HARRIS CA, DESHMUKH M, TSUI-PIERCHALA B, MARONEY AC, JOHNSON EM Jr: Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J. Neurosci. (2002) 22(1):103-113.
  • LAVOIE MJ, CORTESE GP, OSTASZEWSKI BL, SCHLOSSMACHER MG: The effects of oxidative stress on parkin and other E3 ligases. J. Neurochem. (2007) (In Press).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.